HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hiroharu Yamashita Selected Research

Nivolumab

11/2023Alterations in Intratumoral Immune Response before and during Early-On Nivolumab Treatment for Unresectable Advanced or Recurrent Gastric Cancer.
11/2021The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi-institutional cohort study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hiroharu Yamashita Research Topics

Disease

64Stomach Neoplasms (Stomach Cancer)
11/2023 - 11/2004
51Neoplasms (Cancer)
11/2023 - 11/2004
23Neoplasm Metastasis (Metastasis)
12/2022 - 10/2005
13Carcinoma (Carcinomatosis)
01/2023 - 11/2005
10Lymphatic Metastasis
11/2023 - 10/2005
9Ascites
01/2017 - 01/2010
7Esophageal Neoplasms (Esophageal Cancer)
10/2022 - 01/2016
6Sarcopenia
05/2022 - 01/2020
5Esophageal Squamous Cell Carcinoma
07/2022 - 10/2016
5Adenocarcinoma
03/2021 - 10/2005
4Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 09/2005
3Obesity
01/2023 - 06/2020
3Colonic Neoplasms (Colon Cancer)
01/2022 - 09/2005
2Febrile Neutropenia
10/2023 - 01/2009
2Infections
01/2023 - 01/2018
2Pneumonia (Pneumonitis)
03/2021 - 10/2016
2Flatulence
02/2021 - 08/2018
2Pancreatic Neoplasms (Pancreatic Cancer)
01/2021 - 09/2014
2Wounds and Injuries (Trauma)
08/2018 - 01/2010
2Vomiting
01/2018 - 01/2010
1Neutropenia
10/2023
1Small Cell Carcinoma
08/2023
1Inflammation (Inflammations)
01/2023
1Peptic Esophagitis (Reflux Esophagitis)
01/2023
1Postgastrectomy Syndromes
07/2022
1Pneumothorax
06/2022
1Abdominal Abscess
06/2022
1Hepatocellular Carcinoma (Hepatoma)
01/2022
1Duodenal Neoplasms (Duodenal Cancer)
01/2022
1Residual Neoplasm
07/2021

Drug/Important Bio-Agent (IBA)

14Paclitaxel (Taxol)FDA LinkGeneric
10/2023 - 12/2008
8Biomarkers (Surrogate Marker)IBA
11/2023 - 06/2006
7lysophosphatidic acidIBA
01/2017 - 12/2004
5Indicators and Reagents (Reagents)IBA
02/2022 - 03/2007
5ErbB Receptors (EGF Receptor)IBA
09/2008 - 11/2004
4Coloring Agents (Dyes)IBA
10/2020 - 06/2007
3Immune Checkpoint InhibitorsIBA
11/2023 - 01/2021
3B7-H1 AntigenIBA
08/2023 - 01/2021
3RNA (Ribonucleic Acid)IBA
01/2023 - 01/2020
3sphingosine 1-phosphate (sphingosine-1-phosphate)IBA
01/2022 - 11/2004
3C-Reactive ProteinIBA
02/2021 - 10/2005
3Hyaluronic Acid (Hyaluronan)IBA
01/2014 - 06/2007
3Fibrinogen (Factor I)FDA Link
06/2009 - 10/2005
2NivolumabIBA
11/2023 - 11/2021
2Indocyanine Green (Cardio-Green)FDA LinkGeneric
11/2023 - 10/2022
2PlatinumIBA
10/2023 - 12/2022
2HLA Antigens (Human Leukocyte Antigens)IBA
08/2023 - 01/2021
2DNA (Deoxyribonucleic Acid)IBA
01/2023 - 01/2019
2Messenger RNA (mRNA)IBA
01/2022 - 07/2007
2AntigensIBA
01/2022 - 01/2018
2lysophosphatidylinositolIBA
01/2022 - 01/2017
2EnzymesIBA
01/2022 - 07/2007
2Programmed Cell Death 1 ReceptorIBA
02/2021 - 01/2017
2GemcitabineFDA Link
01/2021 - 09/2014
2Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
10/2020 - 12/2015
2Phospholipases A1 (Phospholipase A1)IBA
01/2017 - 03/2015
2PhosphatidylserinesIBA
01/2017 - 03/2015
2LysophospholipidsIBA
01/2017 - 02/2005
2Indigo Carmine (Indigo Blue)IBA
01/2014 - 06/2009
2RacivirIBA
01/2014 - 08/2013
2Aligeron (AS 2)IBA
01/2010 - 01/2009
2Peptide Hormones (Polypeptide Hormones)IBA
09/2008 - 07/2007
2Phosphotransferases (Kinase)IBA
09/2008 - 09/2005
2Lysophosphatidic Acid ReceptorsIBA
01/2006 - 12/2004
2LigandsIBA
02/2005 - 11/2004
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
11/2023
1Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2023
1BilirubinIBA
10/2023
1RamucirumabIBA
10/2023
1taxaneIBA
12/2022
1CarbohydratesIBA
01/2022
1Hematoxylin (Haematoxylon)IBA
01/2022
1Glycerophospholipids (Phosphoglycerides)IBA
01/2022
1SphingolipidsIBA
01/2022
1Eosine Yellowish-(YS) (Eosin)IBA
01/2022
1LyasesIBA
01/2022

Therapy/Procedure

27Gastrectomy
11/2023 - 11/2005
21Drug Therapy (Chemotherapy)
10/2023 - 07/2009
13Esophagectomy
11/2023 - 08/2011
12Therapeutics
11/2023 - 04/2014
10Lymph Node Excision (Lymph Node Dissection)
07/2021 - 01/2010
5Operative Surgical Procedures
10/2023 - 01/2016
5Adjuvant Chemotherapy
12/2022 - 06/2009
4Combination Drug Therapy (Combination Chemotherapy)
03/2017 - 05/2012
3Neoadjuvant Therapy
11/2023 - 09/2019
2Immunotherapy
08/2023 - 04/2018
2Appendectomy
06/2022 - 01/2010
2Pancreaticoduodenectomy
01/2022 - 03/2021
2Radiotherapy
07/2021 - 08/2017
2Chemoradiotherapy
07/2021 - 04/2020
2Length of Stay
03/2021 - 12/2017
2Laparotomy
12/2018 - 01/2014
2Catheters
01/2014 - 08/2013
1Palliative Care (Palliative Therapy)
11/2023
1Cholecystectomy
06/2022
1Transjugular Intrahepatic Portasystemic Shunt
06/2022
1Photochemotherapy (Photodynamic Therapy)
07/2021
1Contraindications
07/2021
1Metastasectomy
07/2021
1Salvage Therapy
07/2021